Skip to main content
Generic Myleran injection to be launched in the US for leukemia patients

A generic version of Otsuka Pharmaceutical's Myleran injection, or busulfan, will be launched in the US by partners Mylan and Aspen Pharmacare. The single-dose vial solution is indicated as a treatment for patients with chronic myelogenous leukemia, in combination with cyclophosphamide, as a conditioning regimen for those who will undergo allogeneic hematopoietic progenitor cell transplantation.

Full Story: